KRAS and neoplasm: We observed that complete responses to KRASG12C inhibition in vivo were dependent on tumor cell–intrinsic IFN signaling, as all mice bearing tumors formed by Ifngr2−/− KPARG12C cells relapsed after MRTX treatment (Fig. 9C), while their sensitivity to KRAS inhibition in vitro remained unaffected (fig.